Magnesium supplementation to prevent cisplatin-induced nephrotoxicity in pediatric cancer (Mg-rPII)

Phase 2, randomised trial of magnesium sulfate in cancer (2 arms), sponsored by The grant for general research in metropolitan hospitals from the Tokyo Metropolitan Government. Primary endpoint: Primary endpoint: proportion of chemotherapy courses with serum creatinine elevation ≥50% from baseline. Started Apr 2019; status: completed.